MDA-MB-175-VII Cells
USD$550.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | MDA-MB-175-VII is a human breast cancer cell line originally derived from the pleural effusion of an adult female patient with infiltrating ductal mammary carcinoma. The cell line is part of a series established from metastatic breast tumors to provide viable, fibroblast-poor epithelial cultures. Specifically, MDA-MB-175 was isolated from six of eight thoracenteses performed on a patient who underwent mastectomy and exhibited recurrent malignant pleural effusions. The tumor cells were consistently viable and cultured successfully across samples, which provided a stable platform for in vitro studies of metastatic breast cancer biology. MDA-MB-175-VII cells are morphologically epithelial and have a modal chromosome number of approximately 49, reflecting an aneuploid karyotype. These cells exhibit relatively slow growth in vitro but have gained scientific interest due to their unique molecular features, including the expression of neuregulin-1 (NRG1) fusion transcripts. In particular, the NRG1-DOC4 fusion observed in this line leads to constitutive activation of the HER3/HER4 receptor pathway, promoting autocrine signaling and cell proliferation. This molecular characteristic has positioned MDA-MB-175-VII as a rare but critical model for studying autocrine HER-family receptor signaling and its pharmacological targeting in breast cancer . Further integration into large-scale datasets such as the Cancer Cell Line Encyclopedia (CCLE) has enabled deeper molecular profiling of MDA-MB-175-VII. These datasets include transcriptomic, mutational, and proteomic information that support the classification of the cell line within the luminal subtype of breast cancers, with modest sensitivity to agents targeting HER-family receptors and PI3K signaling pathways. As such, MDA-MB-175-VII serves as a valuable model for preclinical investigations of targeted therapies and the functional consequences of oncogenic gene fusions in breast cancer. |
|---|---|
| Organism | Human |
| Tissue | Metastatic |
| Disease | Invasive breast carcinoma of no special type |
| Metastatic site | Pleural effusion |
| Synonyms | MDA MB 175 VII, MDA-MB-175VII, MDAMB175VII, MDA-MB-175, MDAMB175, MDA-175, MDA175, MD Anderson-Metastatic Breast-175-VII |
Characteristics
| Age | 56 years |
|---|---|
| Gender | Female |
| Ethnicity | African American |
| Morphology | Epithelial |
| Cell type | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | MDA-MB-175VII (Cytion catalog number 305825) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1400 |
Biomolecular Data
| Isoenzymes | AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1-2 PGM1, 2 PGM3, 1-2 |
|---|---|
| Tumorigenic | Yes; Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells. |
| Mutational profile | Mutation: Gene fusion, NRG1 + HGNC, TENM4, Name(s)=TENM4-NRG1, DOC4-NRG1, Note=In frame. |
| Karyotype | Model number = 84; range = 82 to 89 |
Handling
| Culture Medium | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS + Insulin (5 microgram/ml) |
| Dissociation Reagent | Accutase |
| Doubling time | 112 hours |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
| Metastatic site: | Pleural effusion |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305825-151025 | Certificate of Analysis | 05. Dec. 2025 | 305825 |
-
Required products
Required products
Antibiotic/Antimycotic Solution (100x)Product Overview
Volume: 100 ml
Storage: ≤-15°C
Sterility: Sterile-filtered
Antibiotic/Antimycotic Solution (100x) is a sterile, ready-to-use concentrate designed to reduce microbial contamination risks in cell culture and related laboratory applications. This 100x solution contains a well-established combination of penicillin, streptomycin, and amphotericin B—providing broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi. The formulation is suitable for use in eukaryotic cell cultures, bacterial media, and other contamination-sensitive systems, supporting clean and consistent lab operations.
Application and Benefits Optimized for routine research protocols, this solution is widely used to maintain aseptic conditions in cell culture workflows. It offers reliable performance in contamination-sensitive environments, helping researchers reduce the risk of microbial overgrowth without compromising cell health or experimental reproducibility. The sterile-filtered formulation eliminates the need for additional solubilization steps, supporting streamlined media preparation and reducing variability in daily lab procedures.
Usage and Compatibility To achieve standard working concentrations, dilute the solution 1:100 into your complete culture medium. The product is compatible with a broad range of mammalian cell lines and basal media. With consistent stock availability, researchers benefit from dependable supply continuity and simplified logistics planning. The solution should be stored at ≤ –15 °C and protected from repeated freeze-thaw cycles to maintain stability. For research use only. Not for use in diagnostic or therapeutic procedures. Not for use in humans or animals.USD$45.00* -
Related products
Related products
MDA-MB-175-VII CellsOrganism Human Tissue Metastatic Disease Invasive breast carcinoma of no special type USD$550.00*